INTRODUCTION AND OBJECTIVES: Sacral neuromodulation (SNS) is approved by the Food and Drug Administration for the treatment of refractory urge urinary incontinence, frequency/urgency, idiopathic urinary retention and fecal incontinence. Prior to placement of an implantable pulse generator, all patients must undergo a trial stimulation to ensure improvement in their condition. The success rate for staged SNS implantation of a pulse generator (defined as > 50% improvement) varies greatly in the literature (ranging from 40 to 90%). We sought to determine success rates in California using a statewide registry.
INTRODUCTION AND OBJECTIVES: Sacral neuromodulation (SNS) is approved by the Food and Drug Administration for the treatment of refractory urge urinary incontinence, frequency/urgency, idiopathic urinary retention and fecal incontinence. Prior to placement of an implantable pulse generator, all patients must undergo a trial stimulation to ensure improvement in their condition. The success rate for staged SNS implantation of a pulse generator (defined as > 50% improvement) varies greatly in the literature (ranging from 40 to 90%). We sought to determine success rates in California using a statewide registry.
METHODS: We accessed non-public records from the California Office of Statewide Health Planning and Development (OSHPD) Ambulatory Surgery Database for the years 2005 to 2011. This dataset captures all non-federal ambulatory surgical visits within the state. Appropriate Current Procedural Terminology, 4th edition (CPT) procedure codes and International Classification of Disease, 9th edition (ICD-9) diagnosis codes were used to analyze all SNS procedures and their indication. Patients were followed longitudinally using unique patient record linkage numbers. Staged success was defined as the proportion of patients who received a stage 2 SNS generator implantation after their stage 1 tined lead trial.
RESULTS: We identified 4,098 patients with SNS procedure codes. After excluding patients who only underwent generator exchange, lead revision or lead explantation, our final cohort included 2,765 patients. The majority of patients were female (77%), over 60 years of age (68%), Caucasian (74%) and had Medicare (60%). A total of 1,396 patients underwent a stage 1 trial of tined-lead implantation, of which 962 subsequently underwent stage 2 pulse generator placement (staged success rate of 69%). Staged success rates were 72% for urge urinary incontinence, 69% for urgency/frequency, 57% for urinary retention, 68% for interstitial cystitis and 67% for neurogenic bladder. Success rates were similar after stratification by race/ethnicity and insurance coverage.
CONCLUSIONS: While the success rates for staged SNS implantation in the state of California were less than that observed in many single center academic series; they are better than previously reported for Medicare patients, and suggestive of a success rate of greater than two thirds. 
METHODS: The NCDB identified adult males with testicular germ cell tumors (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . Markers of care delays included: higher stage presentation (stage III+), large primary lesion (>6cm), delayed orchiectomy (>10 days post-diagnosis), and overall mortality. Key risk factors we hypothesized to be associated with care delays included race/ethnicity, socioeconomic factors and insurance status. Outcomes were assessed with multivariable hazards regression (survival) or logistic regression (others).
RESULTS: Among 31,964 men, 17% had higher stage presentation, 29% had a large primary, and 9.9% had delayed orchiectomy and 4.8% died during follow up. All outcomes were significantly associated with multiple risk factors for care delays on multivariable analysis. Between 2004 and 2013, Medicaid coverage increased from 6.6% to 11.2%, and uninsured status increased from 10.4% to 13.1% (Pearson p for linear trend <0.001). The most consistent and greatest magnitude association with poor disease specific outcomes was insurance status (e.g. for mortality HR for Medicaid 1.9, 95% CI 1.6-2.3, and for uninsured HR 1.7, 95% CI 1.5-2.1, for large primary Medicaid OR 1.8, 95% CI 1.7-2.0, uninsured OR 2.1, 95% CI 2.0-2.3 [referent private payer]).
CONCLUSIONS: We find association between severity of disease and markers of poor access to care. Medicaid expansion is a strategy employed to increase coverage by the Affordable Care Act. As such, it will be important to monitor whether gains in coverage translate to improvements in cancer outcomes.
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PD09-10 TEMPORAL TRENDS IN MANAGEMENT AND OUTCOMES OF TESTICULAR CANCER: A POPULATION-BASED STUDY
Michael Leveridge*, D Robert Siemens, Kelly Brennan, Jason Izard, Safiya Karim, Christopher Booth, Kingston, Canada INTRODUCTION AND OBJECTIVES: Treatment guidelines for early-stage testicular cancer have increasingly recommended deescalation of therapy. We sought to describe changes in routine clinical practice and whether this has compromised survival in the general population.
METHODS: The Ontario Cancer Registry was linked to electronic records of treatment to identify all patients diagnosed with testicular cancer and treated with orchiectomy in Ontario during 2000-2010. Treatment after orchiectomy was classified as radiotherapy (RT), retroperitoneal lymph node dissection (RPLND), chemotherapy, or none. Stage of disease at diagnosis was not available. Cancer-specific (CSS) and overall survival (OS) were measured from date of orchiectomy. The chi-squared test was used to evaluate temporal trends in practice patterns; the log-rank trend test was used to evaluate whether outcomes changed over time.
RESULTS: Orchiectomy pathology reports were available for 86% (2821/3281) of all cases in Ontario; the study population included 1580 and 1105 cases of seminoma and non-seminoma (NSGCT); other histologies were excluded. Median age was 34 years. Among patients with seminoma there was a significant increase in the proportion of patients with no active treatment after orchiectomy (from 33% to 66%, p<0.001). Use of RT decreased over time (57% to 18%, p<0.001) and use of chemotherapy remained stable (from 16% to 17%, p¼0.344). Post-orchiectomy practice patterns remained relatively stable among patients with NSGCT: no treatment 29% to 41% (p¼0.221); chemotherapy 69% to 55% (p¼0.203); RPLND 27% to 26% (p¼0.308). Among the 296 patients undergoing RPLND, 61% were performed in the postchemotherapy setting; this proportion remained stable over time (p¼0.423). OS for the entire cohort at 5 and 10 years was 96% and 94%. CSS at 5 and 10 years was 97% and 97%. There was no Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e197
